First of all, we have various price tests. If you have a new cancer drug, let's say the cure for lung cancer, that would be deemed a breakthrough drug. The price that would be permitted under our concurrent guidelines would be the median international price. We would go to the publicly available price in those seven countries and determine the median of that, and this would be the price that would be permitted in Canada.
Let's not forget that provinces have different reimbursement priorities. Whereas Alberta may say we're going to pay for that drug, Prince Edward Island may say the cost-effectiveness is not enough to justify paying for it, and that's why there's a lot of discrepancy across Canada on these major drugs. So they get paid for in Alberta, not in Ontario, and we can't control that.